Drug Discovery

FDA grants two designations for GenFleet’s drug candidate SLS009

Chinese biotechnology company GenFleet Therapeutics has received the US Food and Drug Administration (FDA) designations for its drug candidate SLS009 (GFH009).

Simcha Therapeutics signs license agreement with Janssen for DR-18

Clinical-stage immunobiology company Simcha Therapeutics has signed a licence and option agreement with Johnson & Johnson subsidiary Janssen Biotech for new decoy-resistant IL-18 (DR-18).

AOB Pharma, Maruho partner to develop B244 for inflammatory ailments

AOB Pharma has signed an exclusive license and development agreement with Maruho for the development and marketing of its topical biologic, B244, for inflammatory indications in Japan.

AGC Biologics to build new facility in Japan

AGC Biologics has announced the establishment of a new manufacturing site at the AGC Yokohama Technical Center in Japan.

WuXi XDC, IntoCell partner for drug-linker technology and CRDMO services

WuXi XDC, a China-based CRDMO specialising in antibody drug conjugates (ADCs) and the broader bioconjugate market, has entered into a memorandum of understanding (MoU) with South Korea's IntoCell.

Innovent and SanegeneBio partner for hypertension drug development

Innovent Biologics has signed a partnership agreement with Sanegene Bio to jointly develop an angiotensinogen (AGT) directed siRNA drug candidate, SGB-3908, to treat hypertension.

LimmaTech, AbVacc sign licensing agreement for S. aureus vaccine candidate

LimmaTech Biologics and AbVacc have entered into a licensing agreement, under which the former will get exclusive rights for the continued development of the latter's multivalent toxoid vaccine candidate, LBT-SA7 (previously known as IBT-V02).

Aldevron signs agreement to acquire license to Codex HiCap RNA Polymerase

Aldevron, a US-based developer and manufacturer of plasmid DNA, RNA and proteins for the biotech industry, has signed an agreement with US-based enzyme engineering company Codexis to acquire global exclusive license to Codex HiCap RNA Polymerase.

Almirall signs alliance with etherna for new mRNA-based therapies

Pharmaceutical company focused on medical dermatology Almirall has signed a multi-target alliance with mRNA/LNP technology platform company etherna to discover and develop new mRNA-based therapies to address severe skin diseases, including non-melanoma skin cancer.